🔴 Moleculin Biotech is trading 9.4% down in pre-market; no company-specific announcement identified

Moleculin Biotech is trading at $7.52, down 9.40% in pre-market on November 4; no company-specific announcement explaining the decline was found.

• The latest identified company news was October 30 completion of dosing in Part A of the MIRACLE trial, with a comprehensive data readout expected in Q1 2027.
• That earlier milestone does not establish a reason for the decline; positive biotech-sector context does not explain the move.